The conversion of skeletal myoblasts to terminally differentiated myocytes is negatively controlled by several growth factors and oncoproteins. In this study, we have investigated the molecular mechanisms by which v-Src, a prototypic tyrosine kinase, perturbs myogenesis in primary avian myoblasts and in established murine C2C12 satellite cells. We determined the expression levels of the cell cycle regulators pRb, cyclin D1 and D3 and cyclindependent kinase inhibitors p21 and p27 in v-Srctransformed myoblasts and found that, in contrast to myogenin, they are normally modulated by differentiative cues, implying that v-Src affects myogenesis independent of cell proliferation. We then examined the levels of expression, DNA-binding ability and transcription-activation potentials of myogenic regulatory factors in transformed myoblasts and in myotubes after reactivation of a temperature-sensitive allele of v-Src. Our results reveal two distinct potential modes of repression targeted to myogenic factors. On the one hand, we show that v-Src reversibly inhibits the expression of MyoD and myogenin in C2C12 cells and of myogenin in quail myoblasts. Remarkably, these loci become resistant to activation of the kinase in the postmitotic compartment. On the other hand, we demonstrate that v-Src efficiently inhibits muscle gene expression by repressing the transcriptional activity of myogenic factors without affecting MyoD DNAbinding activity. Indeed, forced expression of MyoD and myogenin allows terminal differentiation of transformed myoblasts. Finally, we found that ectopic expression of the coactivator p300 restores transcription from extrachromosomal muscle-specific promoters.
Introduction
Skeletal muscle differentiation is driven by the activity of a family of muscle-restricted basic helix-loop-helix (bHLH) transcription factors that, in concert with members of the E2A and myocyte enhancer factor 2 (MEF2) families, induce transcription of regulatory and structural muscle-specific genes (reviewed in Molkentin and Olson, 1996; Perry and Rudnicki, 2000) . The four bHLH myogenic regulatory factors (MRFs), MyoD, Myf5, myogenin and MRF4, activate the transcription of target genes by binding to sequence-specific elements, called E boxes, present in enhancers of muscle-specific genes (Lassar et al., 1989a) . Muscle-specific isoforms of the MEF2 transcription factor functionally cooperate with MRFs to activate myogenesis (Molkentin and Olson, 1996) , possibly as a result of both proteinprotein physical interaction and contact-independent mechanisms (Puri and Sartorelli, 2000) . In addition, MyoD and MEF2 transcription factors have been recently shown to interact with the ubiquitous transcriptional coactivators p300/CBP and PCAF, endowed with acetyltransferase activity (Eckner et al., 1996; Sartorelli et al., 1997) , and this interaction appears to be required for the induction of muscle differentiation (Eckner et al., 1996; Puri et al., 1997b) . p300/CBP are involved in multiple transcription events and represent specific targets of viral oncoproteins, such as E1A and SV40 large T antigen that can block skeletal muscle differentiation (Eckner et al., 1996; Puri et al., 1997a; Chan and La Thangue, 2001) .
Individual myoblasts in vivo express various combinations of MRFs, depending on the species and on their position and time of appearance during ontogenesis. In myoblasts transferred to in vitro culture, the situation is somewhat simplified and it is generally agreed that immortalized murine myogenic cell lines express MyoD and/or Myf5 before the differentiation program is activated, whereas the expression of myogenin is achieved upon removal of mitogenic stimuli (Perry and Rudnicki, 2000) , although in C2C12 satellite cells myogenin expression has been occasionally found in dividing cells (Andres and Walsh, 1996) . In unestablished myoblasts derived from avian embryos MyoD, Myf5 and myogenin are expressed in proliferating cells (Pownall and Emerson, 1992; Russo et al., 1997) . Besides governing transcription of muscle-specific genes, MRFs also control irreversible withdrawal from the cell cycle, a prerequisite for myogenic terminal differentiation, by interacting with key cell cycle regulators (reviewed in Maione and Amati, 1997; Walsh and Perlman, 1997; Wei and Paterson, 2001) . It is commonly held that the myogenic potential of MyoD is inhibited in myoblasts by incoming signals, be they mitogenic or positional (Perry and Rudnicki, 2000; Wei and Paterson, 2001) . Several oncogenes, including activated forms of the Src tyrosine kinase, Ras GTPase and the transcription factors Myc, Fos and Jun have been shown to affect differentiation and tissue-specific gene expression when expressed in both primary myoblasts and myogenic cell lines (Alema`and Tato`, 1994; Wei and Paterson, 2001 ), but the downstream signaling pathways are not well understood. The Ras-Raf-MAPK pathway plays a crucial role in transducing extracellular signals generated by growth factors, and several studies have attempted to delineate the role of components of this pathway in muscle differentiation. The mechanism by which Ras inhibits myoblast differentiation, however, remains controversial. The MyoD-transactivating function has been shown to be inhibited by activated Ras in one instance (Lassar et al., 1989b) and to be unaffected in another instance (Kong et al., 1995) . In addition, while myogenin has been shown to represent a crucial target of activated Ras in unestablished quail myoblasts (QMb) (Russo et al., 1997) , it has recently been reported that inhibition of myogenin expression by activated Raf, a Ras effector, is not responsible for the block of myogenesis in chicken myoblasts (Johnson et al., 2002) and that MEF2A is a target of Raf-mediated inhibition in mouse myoblasts, but not in avian myogenic cells (Winter and Arnold, 2000; Johnson et al., 2002) . Moreover, while the MAPK pathway did not appear to mediate the inhibitory effect of activated Ras on muscle cell differentiation (Ramocki et al., 1997) , it has recently been reported that activated MEK1 represses MyoD transactivation through a physical interaction with its transcriptional activation domain (Perry et al., 2001) . These apparent discrepancies might be due to the use of different cell contexts (unestablished cultures versus stabilized cell lines) and experimental approaches (transient versus stable transfectants), or exemplify species differences in the control of myogenesis. In addition, the issue of whether the sustained activation of mitogenic pathways blocks myogenesis by impinging on the regulation of G1 progression or more directly on the transactivation function of MyoD and myogenin, or both, is not yet settled.
In this study, we chose to use two distinct cell systems that faithfully reproduce myogenesis in vitro, the unestablished quail embryo myoblasts and the wellcharacterized muscle satellite cell line C2C12, both transformed with a temperature-sensitive (ts) mutant of the v-src oncogene. There are several reasons for utilizing the v-Src tyrosine kinase, a prototypic oncogenic protein, to study the regulation of skeletal muscle differentiation in vitro: (1) v-Src has long been known to exert pleiotropic effects in many different cell types, often resulting in the inhibition of differentiation (Boettiger, 1989; Alema`and Tato`, 1994; Thomas and Brugge, 1997) ; (2) much information on the role of v-Src downstream effectors such as Ras, Raf and MEK1 in cell transformation is available (Thomas and Brugge, 1997); (3) myoblasts transformed by ts-v-Src exhibit transformation and block of differentiation at the permissive temperature and, upon inactivation of the kinase by shift to the restrictive temperature, fuse into multinucleated myotubes (Falcone et al., 1991) , express muscle-specific proteins and assemble highly ordered sarcomeric structures (Castellani et al., 1995 (Castellani et al., , 1996 . In these cells, where v-Src can be activated at will, it is possible to investigate at the myoblast level the signals promoting the transition to the postmitotic compartment, and at the myotube level the signals underlying the maintenance of the differentiated phenotype (Gallo et al., 1999) .
Here, we demonstrate that v-Src inhibits myogenic differentiation by interfering with the regulation of MRFs at multiple levels without affecting the expression of cell cycle regulators. We find that v-Src reversibly inhibits the expression of MyoD and myogenin in C2C12 cells and of myogenin in QMb. Remarkably, these loci become resistant to activation of the kinase in the postmitotic compartment in both cell types. In addition, we show that v-Src blocks MyoD-transactivating function, without influencing its ability to bind DNA, and that the inhibitory action is targeted to the amino-terminal domain of MyoD. Finally, we find that, whereas transient expression of MyoD and myogenin results in full recovery of terminal differentiation, forcibly expressed p300 only restores transcription from extrachromosomal templates.
Results

Expression of muscle regulatory factors in v-Src-transformed QMb
Unestablished quail embryo myoblasts accumulate high levels of mRNAs for MyoD and myogenin transcription factors both in growing (GM) and differentiation medium (DM), while transcripts for muscle-specific contractile proteins are detected only in DM (Falcone et al., 1991; Russo et al., 1997) . One mechanism by which v-Src inhibits the differentiation of avian myoblasts involves the selective inhibition of transcription of muscle-specific mRNAs and their processing, without altering the expression of the endogenous MyoD gene (Falcone et al., 1991; Yoon and Boettiger, 1994) . A further characterization of the expression levels of avian MRFs was conducted both at the mRNA and at the protein levels. As shown in Figure 1a , a Northern blot analysis revealed that myogenin mRNA was barely accumulated in QMb transformed by wt-v-Src (QMb-PRA) at all temperatures or in QMb transformed by ts-v-Src (QMb-LA29) at the permissive temperature (351C). In the latter cells, myogenin mRNA transcripts were readily accumulated after differentiation at the restrictive temperature (411C) and were not downregulated after reactivation of v-Src by a 2-day shift to 351C. Conversely, Myf5 was expressed in proliferating myoblasts at 351C, but was silenced after differentiation for 2 days at 411C in QMb-LA29 (Figure 1a) .
The distinct regulation of MyoD and myogenin expression by v-Src was confirmed by the analysis of MRFs at the protein level. MyoD protein was synthesized to a similar extent in both transformed myoblasts and differentiated myotubes, as revealed by immunoprecipitation of 35 S-methionine-labeled cell extracts and immunofluorescence with specific antibodies (Figure 1b  and 2a, b) . Myogenin protein expression, examined by immunoblot analysis, was suppressed in QMb-LA29 at 351C, readily resumed at 411C and its accumulation was not affected in postmitotic myotubes shifted to 351C (Figure 1c) . Note that the maximal myogenin expression was observed after 1 day at 411C and a decrease in protein accumulation occurred in the following days, concomitant with the increase of myosin heavy chain (MHC) along with myotube maturation (Figure 1c) . Accumulation of the MRF coactivator MEF2 was also analysed and found to be partially downregulated at 351C in DM in both myoblasts and myotubes (Figure 1c) . These results show that the expression of MRFs and MEF2 proteins is not necessarily abrogated in the presence of an active v-Src kinase.
ts-v-Src reversibly blocks myogenesis in C2C12 myoblasts
Clonal strains of C2C12 cells were generated by infection with retroviral constructs carrying either a wt-v-src (C2C12-SR1) or a ts-v-src (C2C12-MR31) allele or a neomycin-resistance gene (C2C12-neo) as control. The majority of C2C12-src clones exhibited a transformed phenotype. Loss of growth control was manifested by an increased proliferation rate and the acquisition of anchorage-independent proliferation (5-10% soft-agar cloning efficiency). To determine whether the transformation of murine myoblasts by v-Src influenced the expression of myogenic regulators, analysis of MyoD and myogenin transcripts was performed in C2C12-src and C2C12-neo (Figure 3) . A significant inhibition of MyoD mRNA accumulation was evident in two clones of C2C12-SR1 myoblasts maintained either in GM or in DM for 2 days, whereas myogenin mRNA was not upregulated in DM (Figure 3a ) as compared to control C2C12-neo cells (Figure 3b ). Also, in C2C12-MR31 at the permissive temperature (351C) MyoD and myogenin mRNA accumulation was inhibited. Consistent with previous reports (reviewed in Olson and Klein, 1994) , C2C12 cells express very little Myf5 and MRF4 mRNAs in either GM or DM, and their levels of expression were not significantly affected by transformation by v-Src (not shown).
The v-Src-induced inhibition of differentiation was completely reversible in C2C12-MR31 cultured in DM Figure 3b ). In these cells cultured at 391C, MyoD transcripts were detected as early as 12 h following temperature shift in either GM or DM, and continued to accumulate for up to 4 days ( Figure 3b ). Myogenin and MHC expression was also contingent on v-Src inactivation at 391C. Notably, upon shift of fully differentiated myotubes to 351C, MHC mRNA accumulation was reduced while that of MyoD and myogenin remained unaffected by v-Src reactivation ( Figure 3b ). Altogether these data show that in C2C12 myoblasts v-Src inhibits the expression of both MyoD and myogenin and of structural muscle-specific genes. In postmitotic myotubes, however, MyoD and myogenin loci become resistant to v-Src reactivation, as also observed in quail myotubes. Besides the expression of MRFs, we also analysed the effect of v-Src on Id, a negative regulator of myogenesis. Id protein is normally downregulated in myogenic cells following serum removal and overexpression of Id protein has been shown to inhibit partially and delay the differentiation of C2C12 cells (Jen et al., 1992) . We found that the expression of Id mRNA was high in C2C12-SR1 cells both in GM and DM (Figure 3a) , whereas it was normally downregulated in C2C12-MR31 cells differentiated at 391C in DM, and considerably reinduced following activation of v-Src at 351C (Figure 3b ). Thus, v-Src transformation abrogates the serum dependence of Id expression.
v-Src inhibits myogenic differentiation and induces cell proliferation through distinct pathways
Terminal differentiation of skeletal muscle myoblasts is modulated by mitogens and requires an irreversible exit from the cell cycle. We therefore examined the expression of cell cycle-associated proteins, some of which are considered early markers of differentiation, in v-Srctransformed C2C12 myoblasts, as compared to normal cells. Induction of the hypophosphorylated form of pRb by mitogen removal was barely altered in C2C12-SR1 as compared to C2C12-neo, and downregulation of cyclin D1 and upregulation of cyclin D3 were modulated with similar efficiency in C2C12-SR1 cells in serum-free DM as compared to normal C2C12 or to C2C12-MR31 myoblasts induced to differentiate at 391C for 2 days in serum-free DM (Figure 3c ). In addition, expression of the cyclin-dependent kinase (cdk) inhibitor p21 was induced in serum-free DM in spite of the presence of active v-Src, while myogenin and a-actin accumulation was strongly inhibited under the same conditions (Figure 3c) . Hence, the mechanisms of induction of myogenin and p21 in v-Src-transformed C2C12 cells follow distinct pathways. Upregulation of the MEF2 Figure 3c ). It should be noted that the fraction of proliferating C2C12-SR1 myoblasts in DM, measured by 16 h bromodeoxyuridine (BrdU) incorporation, is reduced from 90% at day 1 to 50% at day 3, and from 90 to 30% in C2C12-neo, clearly indicating that both normal and transformed cells are sensitive to mitogen removal. Altogether, these findings indicate that although C2C12-SR1 cells respond to serum deprivation by properly modulating pRb, p21, cyclin D1 and cyclin D3, this is not sufficient for the execution of the myogenic program, as clearly evidenced by the lack of expression in DM of the early differentiation marker myogenin (Figure 3c ).
Since the study of cell cycle-associated proteins in QMb-LA29 myoblasts was hampered by the lack of avian-specific reagents, our analysis was limited to pRb and p27 proteins. The total pRb decreased upon mitogen removal at 351C and differentiation at 411C. In common with C2C12 cells, this drop in accumulation was accompanied by the increase in the hypophosphorylated form that became the major species in myotubes (Figure 4g ). In addition, the hyperphosphorylated species of pRb could be induced in terminally differentiated cells by v-Src reactivation (Figure 4g ), although these cells cannot re-enter the cell cycle (Falcone et al., 1984) . The cdk inhibitor p27 was strongly upregulated in differentiated cells expressing muscle-specific MHC and a-actinin, and was maintained at low levels both in proliferating myoblasts and in myotubes upon v-Src reactivation (Figure 4g ). In order to test whether downregulation of p27 was involved in the inhibition of differentiation, we forcibly expressed p27 in Src-transformed proliferating myoblasts and analysed both the fraction of cells in the S phase by BrdU incorporation and the number of cells expressing endogenous myogenin in DM. Double scoring of the cultures, shown in Figure 4 , indicates that only 2% of the nuclei of myoblasts overexpressing p27 (n ¼ 400) incorporate BrdU (Figure 4a , b), compared to 70% measured in control green fluorescent protein green fluorescent protein (GFP)-positive cells (n ¼ 415) (Figure 4c, d) , and the percentage of myogenin-positive cells (about 5%) is not altered in p27-overexpressing cells (n ¼ 385). Thus, forced expression of p27 causes the cells to exit from the cell cycle, yet does not promote myogenic differentiation, clearly indicating that the two events are separable and regulated through independent mechanisms.
MyoD binds DNA in vitro in the presence of an active v-Src
The activation of complex muscle-specific promoters and enhancers by myogenic bHLH proteins is dependent on the palindromic DNA-binding motif CANNTG, referred to as E-box . To determine whether MRF heterodimers present in nuclei of v-Src-expressing quail myogenic cells would bind the E-box containing sequence (MEF-1 site) of the muscle creative kinase (MCK) promoter, nuclear extracts were prepared from QMb-LA29 myoblasts grown at 351C and differentiated myotubes either maintained at 411C or shifted to the permissive temperature for 2 days, and from quail embryo fibroblasts (QEF), C2C12-neo myotubes and C3H10T1/2-MyoD as controls. Extracts from C2C12-neo myotubes yielded two major bands in the gel shift assay that have been previously shown to consist of complexes of MyoD-and myogenin-E2A proteins ; these complexes were specifically supershifted by anti-MyoD and anti-myogenin antibodies ( Figure 5a ). The identity of the supershifted complex containing MyoD was also confirmed by the analysis of extracts of C3H10T1/2 constitutively expressing MyoD (Figure 5a ). Proliferating QMb-LA29 myoblasts at the permissive temperature contained Figure 3 v-Src inhibits the expression of muscle-specific gene products in C2C12 cells without altering the regulation of pRb, cyclins and cdk inhibitors, (a) Total RNAs of two C2C12-SR1-derived clonal strains were harvested from cells maintained at 371C in sparse cultures in GM or from confluent cells in DM for 3 days and examined by Northern blot analysis. (b) RNAs from C2C12-neo (C2-neo, lanes 1 and 2) or from a C2C12-MR31-derived clone (clone 10) (lanes 3-11) were extracted from myoblasts maintained at 351C in GM (lanes 1 and 3), from cells shifted to 391C in either GM (lane 4) or DM for up to 4 days (lanes 2, 5-8) or differentiated for 2 days in DM at 391C and then shifted to 351C for the indicated time (lanes 9-11). Northern blots were probed for the levels of expression of the indicated RNAs. (c) Western blot analysis of total lysates from C2C12-neo (neo) and C2C12-SR1, clone 5 (SR1), maintained in GM or serum-free DM at 371C, and C2C12-MR31, clone 10 (MR31) either kept in GM at 351C or differentiated in serum-free DM at 391C for 3 days. Lysates normalized for protein content were blotted with antibodies specific for the proteins indicated v-Src blocks myogenesis by targeting MyoD and p300 G Falcone et al several MEF-1 site oligomer-binding activities ( Figure 5b ). The complexes were not formed with incubation in the presence of a 100-fold excess of unlabeled oligonucleotide and were not inhibited by an oligonucleotide containing a mutated MEF-1 site, indicating that they were specific for the E-box. In the presence of anti-MyoD antibodies, a supershift was observed concomitant with a modest reduction in the intensity of the band corresponding to the major complex ( Figure 5b ). Indeed, depletion of MyoD protein from nuclear extracts by immunoprecipitation with specific antibodies inhibited the supershift, confirming that MyoD was present in the complex (Figure 5b ). The supershift was also observed in myotubes kept at 411C or following shift to 351C (Figure 5b ). The available antibodies against avian myogenin worked poorly in this kind of assay, precluding the possibility of assessing whether myogenin complexes competent for DNA binding are present in nuclear extracts from myotubes at 411C and after shift to 351C. These data suggest that MyoD is capable of binding its cognate DNA sequences in vitro in the presence of an active v-Src.
v-Src inhibition of muscle gene activation is targeted to myogenic bHLH factors, likely through the N-terminal activation domain
Having determined the levels of expression of MRFs in transformed myoblasts and in differentiated myotubes shifted to 351C, and their competence to bind E-boxes, we investigated whether v-Src interfered with their ability to transactivate skeletal muscle-specific genes. In order to analyse whether the inhibition of v-Src would be targeted to the E-box elements, we made use of chloramphenicol acetyl transferase (CAT) reporter genes driven by E-box-containing promoters. Table 1 shows that 4R-tk-CAT and MCK-CAT were significantly suppressed in QMb at the permissive temperature as well as in differentiated myotubes after reactivation of the tyrosine kinase. Control tk-CAT, bactin-CAT and Rous sarcoma virus (RSV)-CAT reporters were found to be expressed at comparable levels in all conditions, thus confirming the specificity of v-Src in the inhibition of MRF-responsive promoters. We could not determine the transactivating activity of MEF2 proteins in QMb-LA29, due to the high levels of basal The MyoD protein carries three functionally separable domains: the basic region, the HLH and the Nterminus activation domain. To determine the domain/s specifically targeted by v-Src, we used fusion proteins of the DNA-binding domain of Gal4 to full-length MyoD (Gal-MyoD), to the N-terminal activation domain of MyoD (Gal-N) or to deletion mutants of MyoD lacking either the basic domain (Gal-Dbasic) or the HLH domain (Gal-DHLH). Fusion proteins of Gal4 to the activation domain of E1A and VP16 were also tested as controls. All these fusion proteins can activate a cotransfected CAT reporter construct carrying multimerized copies of Gal4 DNA-binding sites (Gal-CAT) (Johnston et al., 1992) . As shown in Table 1 , GalMyoD, Gal-N, Gal-Dbasic and Gal-DHLH all activated Gal-CAT only at 411C, and were significantly inhibited when transfected in myotubes at 411C and assayed after a downshift to the permissive temperature. Transactivation by Gal-E1A (Table 1) and Gal-VP16 (not shown) was not affected at either temperature. From these data, we infer that v-Src-mediated repression of MyoD activity is targeted to the MyoD N-terminal transactivation domain and this region is likely to represent the major site of v-Src inhibitory signal.
Rescue of myogenesis in QMb and C2C12 cells upon forced expression of MRFs
Since myogenin expression is abrogated in v-Srctransformed quail and C2C12 myoblasts and MyoD expression is inhibited only in C2C12 cells, we asked whether restored expression or overexpression of the MRFs in both cell types would rescue the myogenic phenotype of transformed myoblasts. To this aim, QMb-LA29 and C2C12-MR31 cells were transfected at 351C with MyoD or myogenin expression vectors and Figure 5 Expression of v-Src does not inhibit binding of MyoD to the E-box elements of the MCK enhancer. Electrophoretic mobility shift assays were performed using an end-labeled double-strand probe and 5 mg of nuclear proteins from the indicated cell types. Before electrophoresis, DNA-protein complexes were incubated with 0.1 ml of either preimmune (PreImmune) serum or antibodies to MyoD (a-MyoD, R4). As a control, preincubation with 100-fold excess unlabeled oligonucleotide ( Â 100 E-box) or mutated E-box (mutated E-box) was carried out. The supershifted species are indicated (arrow). (a) Antibodies to MyoD specifically induced a supershift of the DNA-protein complexes in nuclear extracts prepared from C2C12-neo (C2C12) and C3H10T1/2-MyoD (C3H-MyoD) in DM. A distinct supershifted band was induced by antibodies to myogenin (F5D) in C2C12-neo. (b) Nuclear extracts from QMb-LA29 in DM at 351C, at 411C (411C) or differentiated at 411C and shifted to 351C for 2 days (41/351C) and from QEF were challenged with anti-MyoD antibodies. In order to confirm the presence of MyoD in the complexes, extracts from QMb-LA29 at 351C were preincubated with preimmune (PI/a-MyoD*) or antiMyoD (a-MyoD/a-MyoD*) sera and, following removal of the immunocomplexes, were incubated with fresh antibodies to MyoD. Depletion of MyoD protein from the nuclear extracts clearly prevented the formation of the supershifted species. Note that nuclear extracts in (a and b, right panel), were prepared as in Gossett et al. (1989) and in (b, left panel), as in Lassar et al. (1991) analysed for transcription of cotransfected musclespecific promoters and for expression of endogenous skeletal muscle proteins by single cell immunofluorescence analysis. As shown in Figure 6 , overexpression at 351C of either MyoD or myogenin in QMb-LA29 (panels a and b) and C2C12-MR31 (panels c and d) myoblasts restored transcription from 4R-CAT and MCK-CAT promoters to levels comparable to those observed in differentiated myotubes at the restrictive temperature (411C for quail and 391C for murine cells). In addition, both wt-Src-and ts-Src-transformed QMb transfected with MyoD or myogenin at 351C differentiated terminally, as evidenced by the induction of endogenous myogenin and muscle-specific myosin expression, which increased from 10% in myoblasts transfected with control DNA to 70-80% in cells transfected with either MRF (Figure 7a, b) . Similar to QMb, forced expression of MyoD or myogenin in C2C12-MR31 myoblasts at 351C induced the expression of endogenous muscle-specific myosin and troponin T (70%), compared to controls transfected with GFP expression vector (10%) (Figure 7c ). Immunostaining with anti-myosin antibodies also revealed that about 50% of myoblasts transfected with myogenin or with MyoD acquired the competence to fuse into myotubes (not shown). The ability of overexpressed MyoD to overcome the v-Src-dependent block of differentiation was confirmed by experiments of infection of QMb with MyoD adenoviral vectors. Infected cells exhibited extensive fusion into large myotubes and expressed muscle-specific proteins, as assessed by immunofluorescence and Western blot analysis (data not shown). In contrast to MRFs, forced expression of the MEF2C transcription factor resulted in neither enhanced transcription from muscle-specific promoters (not shown) nor expression of muscle proteins (Figure 7a ). Altogether, these results clearly indicate that in QMb-LA29 the block of transition to the postmitotic compartment is due to the lack of expression of myogenin and to the impairment of MyoD-transactivating function by v-Src. Restored myogenin expression is . After transfection, QMb-LA29 and C2C12-MR31 were kept at 351C in DM for 2 days, while controls transfected with empty vectors were shifted to 41 and 391C, respectively, for 2 days. Relative normalized reporter activity is given as fold increase overexpression at 351C in DM (a-d) in control cells transfected with empty vector (referred to as 1). CAT activity was normalized by cotransfection with a bgalactosidase expression vector (pCMV-b, 0.2 mg) and expressed as a ratio of the CAT activity of each test plasmid to the positive control plasmid, RSV-CAT (% test activity/RSV activity) (Pinney et al., 1995) . All transfections were performed in duplicate and at least three independent experiments were performed for each promoter. A representative experiment is shown in the graph p300 relieves the block of transcription of extrachromosomal muscle-specific promoters in v-Src-transformed myoblasts p300/CBP and PCAF have been shown to be necessary coactivators of MyoD in the induction of musclespecific gene transcription (Eckner et al., 1996; Puri et al., 1997b) . In particular, CBP and p300 directly interact with the N-terminal transactivation domain of MyoD (Sartorelli et al., 1997) . Expression levels and associated histone acetylase activity of p300/CBP proteins were not significantly altered in QMb-LA29 at 351C, as compared to differentiated myotubes (data not shown). We then tested the hypothesis that v-Src blocks myogenesis by interfering with the functional interaction of MyoD with p300/CBP by changing their ability to act as coregulators. Transient overexpression of p300 at 351C, alone or in combination with MyoD or myogenin, rescued transcription from muscle-specific promoters in both QMb-LA29 (Figure 6a , b) and C2C12 myoblasts (Figure 6c, d) . In QMb-LA29 also CBP could rescue transcription from the MCK promoter, although at lower levels (data not shown). Similarly, two truncated versions of p300, p300D1472-1522 and p300D1603-1653, lacking acetylase activity but still capable of activating transcription (Puri et al., 1997b) , were found to function as coactivators in transcription from MCK-CAT (data not shown). It is conceivable that ectopically expressed p300/CBP in transformed QMb may recruit the endogenous MyoD, enabling it to activate transcription. In C2C12-MR31 myoblasts, p300 was inactive in promoting 4R-CAT transcription, while it strongly activated the promoter when cotransfected with either myogenin or MyoD ( Figure 6c) ; instead, p300 alone was sufficient to transactivate the more complex MCK promoter (Figure 6d ), probably by interacting with endogenous transcription factors binding to adjacent regions within the promoter. Surprisingly, forced expression of p300/CBP and PCAF, neither alone nor in combination, was capable of recovering the expression of endogenous musclespecific proteins in both QMb-LA29 and C2C12-MR31 myoblasts at the permissive temperature (Figure 7a, c) . The observation that an excess of p300/CBP can bypass v-Src inhibition of transcription from muscle-specific extrachromosomal promoters strongly indicates these coactivators as potential targets of v-Src in blocking terminal differentiation. However, the expression of endogenous muscle-specific proteins cannot be rescued by p300/CBP, suggesting that other levels of inhibition downstream to p300/CBP are present in transformed cells, such as, for example, the state of chromatin at endogenous loci, which may need to be altered in order to rescue full differentiation (Figure 8 ).
Discussion
When cultured in the presence of growth factors, skeletal myoblasts are unable to exit the cell cycle and progress to the ultimate compartment of the myogenic lineage. Thus, myogenesis has been the model of choice in the quest for understanding the control of terminal differentiation during cell transformation (Alema`and Tato`, 1994; Perry and Rudnicki, 2000) . Surprisingly, although several positive and negative regulators have been identified, few studies have focused on the dissection of the levels at which activated oncogenes intercept the myoblast-myocyte transition. Myoblasts transformed by a thermolabile v-Src offer the distinct advantage of studying how the kinase affects both the transition to the myotube compartment and the maintenance of the differentiated phenotype (Alema`and Tato`, 1994; Castellani et al., 1996) . The major conclusion from this work is that v-Src may modulate a number of functional properties of the MyoD family of transcription factors, including their expression in the myoblast compartment and their potential as transcriptional activators in both the myoblast and the myocyte compartments of the lineage. Importantly, we demonstrate that both effects can be divorced from exiting the cell cycle, and that the inhibitory effect on myogenesis partly reflects a defective functional interaction of v-Src with a class of transcriptional coactivators (p300/CBP).
Myogenic differentiation and cell cycle arrest are separable events in v-Src-transformed myoblasts
Besides inducing muscle-specific gene expression, myogenic bHLH proteins, when overexpressed in several cell lines, exert a growth-suppressive effect (Crescenzi et al., 1990) . It is likely that MyoD can promote cell cycle arrest by induction of the cdk inhibitor p21 (Guo et al., 1995; Halevy et al., 1995) and upregulation of pRb (Martelli et al., 1994) . The function of pRb is regulated through phosphorylation by cdks during the G1/S transition, while it becomes hypophosphorylated and functional during differentiation (reviewed in Wei and Paterson, 2001 ). The expression in muscle cells of most cyclins is downregulated at the onset of terminal differentiation (Maione and Amati, 1997; Wei and Paterson, 2001) , with the exception of cyclin D3 (Kiess et al., 1995) . Accordingly, cyclin D1 overexpression has been reported to inhibit myogenesis , presumably through induction of nuclear translocation of cdk4 and the formation of a MyoD-cdk4 inactive complex (Zhang et al., 1999) and by blocking the association of MEF2 with the coactivator GRIP-1 (Lazaro et al., 2002) . Upon mitogen removal, v-Srctransformed C2C12 myoblasts do not upregulate myogenin or muscle-specific genes, yet pRb is found predominantly in the hypophosphorylated form and cyclins and p21 are modulated as in normal myoblasts. This analysis clearly indicates that exit from the cell cycle and block of differentiation are regulated through independent mechanisms (Figure 8 ). Forced expression of the cdk inhibitor p27 can enhance the efficiency of MyoD-initiated muscle differentiation in culture (Zabludoff et al., 1998) . In QMb-LA29, however, p27 only appears to block S phase entry without relieving the block of differentiation imposed by the oncogene, thus reinforcing the notion that exit from the cell cycle and execution of the myogenic program are controlled separately by v-Src in differentiating myogenic cells. This phenotype on the one hand helps define the steps during myogenesis that are critical targets of v-Src, and on the other hand it suggests that these events are subjected to differential regulation during terminal differentiation of skeletal muscle cells. In this connection, it is intriguing that dominant-negative SWI/SNF chromatin-remodeling enzymes impose a very similar phenotype, characterized by full inhibition of the expression of myogenin and downstream muscle genes in spite of the proper regulation of cell cycle-associated proteins including p21, D cyclins and pRb (de la Serna et al., 2001b).
MRF expression and transactivation function are reversibly inhibited by v-Src
Repression of MRF genes at the transcriptional level is induced by growth factors (Vaidya et al., 1989) and oncogenes such as E1A (Caruso et al., 1993) , activated ras (Lassar et al., 1989a, b; Russo et al., 1997) and v-myc (La Rocca et al., 2002) . One level of inhibition of muscle differentiation by v-Src is on the expression of MyoD and myogenin in C2C12-SR1 myoblasts and of myogenin in QMb-LA29. Therefore, MRFs appear to be key targets of the oncogene. We could not assay specifically MEF2-dependent transactivation in v-Src-transformed myoblasts, due to the high basal activity present in these cells. However, it is worth noting that, in contrast to MyoD and myogenin, forced expression of MEF2C in transformed myoblasts did not induce terminal differentiation, suggesting that this transcription factor is not a major target of v-Src. The observation that both MyoD and myogenin loci, while sensitive to v-Src in the myoblast compartment, become resistant to the reactivated kinase in the myotube compartment suggests the existence of a previously unknown level of regulation that would ensure the stability of the differentiated phenotype. In both avian and murine terminally differentiated cells, however, MyoD and myogenin are present but accumulation of muscle-specific mRNAs and transcription from muscle-specific promoters are strongly attenuated, indicating that regardless of the mechanisms by which transcription from these loci is maintained, in the presence of an active v-Src neither MRF is able to execute muscle-specific gene transcription, when expressed at physiological levels ( Figure 8) . The experiments described here indicate that, whereas MyoD maintains, the competence to bind DNA in vitro, its transactivation function is strongly inhibited by vSrc. Notably, v-Src-mediated repression of MyoD activity appears to be exerted through the MyoD Nterminal transactivation domain. In undifferentiated proliferating myoblasts in culture, MyoD is rendered transcriptionally inactive by several mutually reinforcing mechanisms that appear to be under the control of serum mitogens (Perry and Rudnicki, 2000; Puri and Sartorelli, 2000) . One possibility is that in the absence of these external cues, v-Src utilizes some of the mechanisms identified in order to repress myogenesis. In line of principle, the inhibition of MRF function could be obtained by post-translational modifications of MRFs themselves (e.g. phosphorylation) or by altering protein-protein interactions with other components of the complexes engaged in transcription of muscle-specific genes. Our observation that MyoD binds E-boxes in vitro appears to rule out phosphorylation events previously described as exerting the inhibition of MyoD binding to DNA (Liu et al., 1998) . Tyrosine phosphorylation of MyoD at the Nterminus by the nuclear c-Abl tyrosine kinase has recently been found to correlate with inhibition of its transactivation function . MyoD, however, is not tyrosine phosphorylated in v-Srctransformed myoblasts (unpublished observation).
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It has been proposed that the N-terminus domain is required for the repression of MyoD activity and differentiation caused by MEK1 overexpression in C2C12 myoblasts (Perry et al., 2001) . The Ras-ERK pathway is constitutively activated in v-Src-transformed myoblasts (Castellani et al., 1995) , and a constitutively active MEK1 allele efficiently inhibits terminal differentiation in QMb (unpublished results). However, we did not detect MEK1/MyoD-containing complexes in immunoprecipitates from extracts of QMb-LA29, thus making it unlikely that binding of activated MEK1 to MyoD mediates v-Src inhibition of MyoD function. Alternatively, the Ras-MEK1 pathway could inhibit differentiation in QMb-LA29 through other mechanisms such as c-Jun activation. The functional antagonism between c-Jun and MyoD has been attributed to their competition for limiting amounts of essential coactivators, such as p300/CBP (Wei and Paterson, 2001) . Since v-Src activates the AP-1 complex in other cell contexts (Welham et al., 1990) and in myoblasts (unpublished observations), and p300 overexpression can rescue muscle-specific transcription in QMb-LA29, it could be speculated that c-Jun mediates inhibition of myogenic differentiation downstream of v-Src. Induction of AP-1 activity by v-Src in both myoblasts and myotubes is probably mediated by the ERK pathway (Castellani et al., 1995) , whereas jun N-terminus kinase (JNK) is not appreciably activated in these cells (Gallo et al., 1999) .
P300 only rescues transcription from extrachromosomal templates
Factors that can rearrange or alter chromatin structure, such as acetylation by PCAF (Sartorelli et al., 1999; Polesskaya et al., 2000) or the exposure to inhibitors of deacetylases (Iezzi et al., 2002) , are certainly required for activation of genes that were previously maintained in an inactive state. We have not analysed the state of MyoD acetylation in vivo, but thricostatin A, a deacetylase inhibitor, only marginally induced the differentiation of QMb-LA29 (unpublished observations), suggesting that modulation of acetylation does not play a major role in v-Src-induced inhibition of differentiation.
The transcriptional coactivators p300/CBP represent potential targets of v-Src since they are required to ensure full myogenic transcription and differentiation and they are ubiquitously expressed (Puri and Sartorelli, 2000; Chan and La Thangue, 2001) , thus justifying the influence exerted by v-Src on the differentiation programs of several cell types (Alema`and Tato`, 1994; Thomas and Brugge, 1997) . More cogently, the Nterminus of MyoD is involved in the interaction with p300/CBP (Sartorelli et al., 1997) . Although the expression of these coactivators is not altered in v-Srctransformed myoblasts, their function could be inhibited as reported for E1A and large T Antigen (Puri et al., 1997a) . Our results show that v-Src inhibitory effect on the transcription of muscle-specific promoters can be overcome by transient overexpression of either MRFs or p300 in C2C12 and QMb. However, overexpression of MyoD and myogenin, but not that of p300 or MEF2C, efficiently restores the expression of endogenous musclespecific proteins, thus confirming that MRFs represent key targets of the kinase. The finding that p300 relieves the negative regulation imposed by v-Src on transactivation by MRFs highlights a potential level of regulation that can be targeted by the oncogene. However, the observation that overexpression of p300 can only rescue transcription from extrachromosomal templates suggests that additional factors besides p300 are a target of v-Src. Indeed, v-Src-transformed myoblasts may represent a cell model for the identification of gene products that cooperate with MRFs and p300 in ensuring execution of the myogenic program. In a similar instance, constitutively active forms of the small GTPases RhoA and Cdc42 induce expression of extrachromosomal SRF reporter genes, but only Cdc42 can efficiently activate a chromosomal template. Both JNK-dependent and -independent signals, such as histone hyperacetylation, can cooperate with RhoA to activate chromosomal SRF reporters (Alberts et al., 1998) . In addition, we found that in v-Ras-transformed QMb, similar to QMb-LA29, overexpression of p300 restored transcription from muscle promoters but not the expression of endogenous muscle-specific proteins (unpublished results), thus suggesting that Ras and Src utilize common pathways to alter myogenic differentiation.
Recent work has indicated that muscle-specific gene expression induced in fibroblasts by all MRFs requires SWI/SNF chromatin remodeling enzymes (de la Serna et al., 2001b; Roy et al., 2002) and that failure to induce muscle gene expression correlates with inhibition of chromatin remodeling in the promoter region of endogenous differentiation-specific loci (de la Serna et al., 2001a). As discussed above, the similarity in the phenotypes imposed on myoblasts by v-Src and by dominant-negative SWI/SNF makes it attractive to speculate that the activity of the SWI/SNF complex is affected by v-Src in transformed myoblasts. MyoD and myogenin, when overexpressed in v-Src myoblasts, would bypass v-Src-induced inhibition by recruiting the chromatin remodeling enzymes and transcriptional coactivators necessary to activate muscle-specific gene expression, whereas access of overexpressed p300 to the same chromosomal loci is prevented by inhibitory factors (Figure 8) .
Previous studies have shown that forced expression of MRFs partially restores terminal differentiation in Ras-transformed myoblasts (Lassar et al., 1989a, b; Konieczny et al., 1989; Russo et al., 1997) . Block of differentiation induced by c-Myc was found instead to be resistant to myogenic reversion by overexpression of MRFs (Miner and Wold, 1991) . These different outcomes appear to reflect the distinct mechanisms through which Ras, Src and Myc proteins inhibit myogenic differentiation (Alema`and Tato`, 1994) . The results of this study suggest that v-Src blocks myogenic differentiation by targeting the function of MRFs, possibly by acting at the level of their interaction with essential v-Src blocks myogenesis by targeting MyoD and p300 G Falcone et al ubiquitous coregulators that control chromatin remodeling. Given that v-Src interferes with differentiation at a programmatic level (Boettiger, 1989; Thomas and Brugge, 1997) , it is proposed that the mechanisms outlined here can be operating in other cell types. Work is in progress to identify the cytoplasmic signaling pathways activated by v-Src that convey the inhibitory signal from the cell periphery to the nucleus eventually leading to block of muscle-specific transcription.
Materials and methods
Cell culture and viruses
Primary cultures of QMb (Coturnix japonica) and QEF were prepared and propagated as described previously (Falcone et al., 1991) . Differentiation of myogenic cells was induced by substituting GM with an F14 medium supplemented with 2% fetal calf serum (FCS) (referred to as the differentiation medium or DM). Polyclonal populations of transformed QMb were established from primary passage cultures infected at high multiplicity with high titer viral stocks of wild type (wt) PR-A and a ts mutant of RSV, ts LA29. Transformed wt PR-A and ts LA29 quail myoblasts (QMb-PRA and QMb-LA29) were propagated at 351C on collagen-coated dishes in GM. Myogenic differentiation was assayed at 411C in DM. For expression of MyoD by adenoviral vector, QMb-LA29 were infected at high multiplicity with an Ad5-derived, E1A-deleted, adenovirus expressing the full-length murine MyoD cDNA under the transcriptional control of RSV LTR (provided by C Murry). Expression of v-Src in C2C12 cells was achieved by infection with the retroviral construct MR31 (C2C12-MR31), carrying the ts-v-src gene of LA31-RSV and the G418 resistance gene, and the retroviral construct SR-1 (C2C12-SR1), which carries the wt-v-src gene from SR-A RSV and the G418 resistance gene (Gallo et al., 1997) . Clonal strains of transformed myoblasts were isolated by plating infected cells in 0.35% soft-agar and picking colonies after 10 days. Control C2C12 cells expressing the G418 resistance gene (C2C12-neo) were obtained by infection with the retroviral vector Zip-neo and selection with G418. C3H10T1/2 and C3H10T1/2-MyoD (provided by M Caruso), C2C12-neo myoblasts and v-Src derivatives were maintained in DMEM supplemented with 20% FCS (GM) and 0.5 mg/ml of G418. Muscle differentiation was induced by incubating the cultures in DMEM with 2% horse serum (DM) or DMEM containing 10 mg of insulin and 10 mg of human transferrin/ml (serum-free DM).
RNA isolation and Northern blot analysis
Total RNA was prepared and analysed by Northern blot as described (Falcone et al., 1991) . For detection of musclespecific and constitutive transcripts, inserts of the following plasmids were used as probes: cC128, containing a 500 bp quail MHC cDNA; pQmf3, containing a 1.4 kb cDNA fragment encoding the quail homologue of myf-5 (provided by C Emerson); pCmd-1, containing a 1.5 kb chicken MyoD cDNA; pCmgn-1, containing a 1.0 kb chicken myogenin cDNA (obtained from B Paterson); pEMC11S, containing a 1.5 kb mouse MyoD cDNA (obtained from H Weintraub); pEMSVmyogenin, containing a 1.4 kb rat myogenin cDNA (obtained from W Wright); pMH18DR, containing a 1.2 kb mouse Id cDNA (obtained from H Weintraub); pMHC-25, containing a 0.4 kb mouse MHC cDNA (obtained from A Felsani); pBS/ KS-Myf5, containing a 1.5 kb human Myf5 cDNA (obtained from H Arnold); p-EMSV-MRF4, containing a 1.3 kb rat MRF4 cDNA (obtained from S Konieczny); a plasmid containing a 1.2 kb avian GAPDH (glyceraldehyde-3-phosphate-dehydrogenase) cDNA (obtained from C Schneider).
Transient DNA transfections
Cells for transient expression of CAT reporter constructs were transfected in duplicate using the BES/calcium phosphate precipitation technique as previously described (Falcone et al., 1991) or with lipofectamine (Gibco-BRL). C2C12-MR31 cells were transfected in GM with lipofectamine, switched to DM and harvested after 2 days. Myoblasts for transient overexpression of MRFs, coactivators and control proteins were transfected with 0.4-2.0 mg/dish of expression vectors for bgalactosidase (pCMV-b, Clontech), GFP, pGreen-Lantern, Gibco BRL), mouse MyoD and myogenin (see above), hemoagglutinin-(HA)-tagged mouse MEF2C (pcDNA3-HA-MEF2C, from S Lorenzetti and F Tirone), HA-tagged human p300 (pCMV-b-p300-HA, from R Eckner) and FLAG-tagged human pCAF (pCX-Flag-P/CAF, from L Puri). Rescue of the expression of endogenous genes was assayed at the single cell level by immunofluorescence (see below). For the experiments of BrdU incorporation, QMb were transfected with the pGreen-Lantern expression vector alone (0.2 mg/35 mm plate) or along with a fivefold excess of the pBABE-p27 vector (1 mg/ 35 mm plate, provided by M Grossi) using lipofectamine, maintained in DM for 30 h and labeled with 20 mm BrdU for 16 h. In order to evaluate the number of proliferating C2C12-neo and C2C12-SR1 in serum-free DM, cells kept in culture for up to 3 days were labeled with 20 mm BrdU for 16 h, then fixed and processed for immunofluorescence.
CAT assay
Reporter genes for muscle-specific expression were: the pCKCATe4 reporter, containing the mouse MCK enhancer cloned upstream of the MCK basal promoter (Sternberg et al., 1988) ; the cardiac a-actin-CAT reporter, kindly provided by B Paterson; the 4R-tk-CAT reporter gene that contains four copies of the MCK promoter right E-box site immediately upstream of the thymidine kinase (tk) promoter and the parental tk-CAT containing only the tk minimal promoter ; the Gal-CAT, Gal-MyoD, GalDBasic, Gal-DHLH, Gal-N, Gal-VP16, Gal-E1A have been described (Johnston et al., 1992) and provided by S Tapscott. Control CAT constructs contained the chicken a-actin 5 0 regulatory region and the RSV promoter (provided by B Paterson). CAT activity was assayed in total cell extracts either by an enzymatic immunoassay (Roche) or by a radiometric method, as previously described (Falcone et al., 1991) . When reporter genes were transfected alone, CAT assays were normalized to equivalent amounts of proteins. When more than one DNA was transfected, CAT activities were corrected and normalized by cotransfection of pCMV-b. b-Galactosidase activity was assayed with the chlorophenolred-b-dgalactopyranoside substrate.
Antibodies and immunostaining procedures
A panel of antibodies to MyoD was generated in rabbits by injection of the mouse (R4, R8) and quail (R5) MyoD proteins produced in Escherichia coli as fusion products with 210 aa of the phage protein T10 (in collaboration with F Tato`and M Crescenzi). Anti-MyoD sera have been characterized in myogenic mammalian cells and in primary avian myoblasts by immunoprecipitation, mobility shift and immunofluorescence. Note that R4 recognized both murine and avian MyoD v-Src blocks myogenesis by targeting MyoD and p300 G Falcone et al proteins. Anti-chicken myogenin sera were provided by B Paterson. Monoclonal antibody to MyoD (5.8A) was obtained from DakoCytomation and to p27 from Transduction Laboratories. Monoclonal antibody to murine myogenin (F5D) was the gift of G Cossu. Polyclonal antibody to p21 was provided by C Schneider. Monoclonal antibody to pRb (PMG3-245) was obtained from PharMingen. Polyclonal antibodies against D1 and D3 cyclins and MEF2 (C-21) were obtained from Santa Cruz. Monoclonal antibodies to BrdU (clone BU-1) and to troponin T were obtained from Amersham. Monoclonal antibody to avian vinculin (VN3-24) was purchased from Developmental Studies Hybridoma Bank. Monoclonal antibodies to skeletal a-actinin (9A2B5) and myosin (MF20) were the gift of D Fischman. Rabbit polyclonal antibodies to skeletal myosin were developed in house as described in Castellani et al. (1996) . Monoclonal antibodies to myc-tag (9E10) and to HA-tag (12CA5) were provided by G Evan and by G Blandino, respectively. Anti-FLAG (M2) and anti-a-sarcomeric actin (5C5) antibodies were purchased from Sigma. TRITC-and FITC-conjugated goatanti-mouse and anti-rabbit, were obtained from Jackson ImmunoResearch, and horseradish peroxidase-conjugated goatanti-mouse and goat-anti-rabbit were obtained from Bio-Rad.
Immunofluorescence experiments were performed on cultures routinely fixed for 10 min in 4.0% paraformaldehyde, permeabilized with 0.2% Triton X-100 and incubated with the appropriate antibody, as described in Castellani et al. (1995) . Before mounting in Gelvatol, nuclei were counterstained with 0.5 mg/ml of Hoechst 33258. Stained cells were examined using an Olympus microscope equipped with Â 10, Â 40 and Â 60 lenses. Images were recorded on a CCD camera and processed using a DeltaSystem and Adobe Photoshop software.
Immunoprecipitation and Western blot analysis
Cultures of QMb-LA29 were labeled with 160 mCi/ml of methionine/cysteine (ICN) in methionine and cysteine-free DMEM (Flow) supplemented with 4% dialysed FCS at the two temperatures for 3 h. Lysates, obtained as previously described (Gallo et al., 1997) , were immunoprecipitated with preimmune or anti-MyoD serum (R5) and analysed on 10% SDS-PAGE.
Cell extracts for Western blot analysis were carried out as described (Gallo et al., 1999) . Note that in order to solubilize all pRb protein, that is rather insoluble (Martelli et al., 1994) , extraction was also performed in a boiling SDS sample buffer. Western blots were carried out as described (Gallo et al., 1999) .
Nuclear extracts and gel mobility shift assays
Nuclear extracts from v-Src-transformed QMb and C2C12 cells were prepared as in Gossett et al. (1989) and as in Lassar et al. (1991) . Double-stranded oligonucleotides containing wild-type MCK right E-box site (5 0 -GATCCCCCCAA-CACCTGCTGCCTGA-3 0 ) and mutant MCK right E-box site (5 0 -GATCCCCCCAACACGGTAACCCTGA-3 0 ) were used in electrophoretic mobility shift assays. A total of 5-20 mg of nuclear extract proteins were incubated with 0.2 ng of labeled probe in binding buffer containing 0.5-1.0 mg of poly(dI-dC). Antibodies were added after attainment of the complex and incubated for further 15 min. Samples were loaded onto 5% nondenaturing polyacrylamide gels and run in 0.5 Â TBE for 2 h at room temperature.
